Cancer Drug Arthritis Recurs Because Immune Cells Remember — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- MD Anderson and Yale researchers found that recurring arthritis after cancer immunotherapy is driven by memory immune cells—CD8 T cells and PD-1/CXCL13-expressing CD4 T cells—that reappear during later flares rather than launching a new response.
- Approximately 20% to 50% of patients who develop inflammatory arthritis from immune checkpoint inhibitors experience repeated flares, with symptoms persisting months or years after treatment ends.
- Published in Cancer Immunology Research and co-led by Roza Nurieva, Synat Keam, and Yuanteng Jeff Li at MD Anderson alongside Sang Taek Kim at Yale, the study analyzed joint fluid from just six patients across their first and recurring arthritis episodes.
- Recurring immune cells produced increased inflammatory signaling molecules during later flares, and regulatory T cells—normally a brake on immune activity—paradoxically began producing inflammatory molecules.
- Inflammatory cell communication networks within affected joints became more pronounced during the second arthritis episode, indicating a coordinated and intensifying inflammatory environment.
- The researchers proposed the two identified immune cell populations as potential biomarkers to help clinicians recognize patients at risk for recurring arthritis, though the six-patient sample requires larger confirmatory studies.
Why it matters: For the 20–50% of cancer immunotherapy patients who experience recurring arthritis, this six-patient study offers the first mechanistic explanation: memory immune cells drive each flare rather than generating fresh ones. The unexpected finding that regulatory T cells switch from suppressing inflammation to producing it directly challenges assumptions about why these flare-ups intensify.
Ask SkimNews
